MedPredict
MedPredict Thought Leader Insight
User ID:
Password:
  For Pharma and Biotech Decision-Makers LATEST PUBLICATIONS  

One of your key challenges is to stay on top of the latest activities in your target therapeutic areas. What’s happening with competitive compounds in the pipeline? What are their indications and marketing claims likely to be? How are trends in clinical practice evolving, and how will that affect your current and future business?

MedPredict delivers the insights that will drive your strategic decision-making, but without the big price tag and long lead-time required to conduct your own thought leader interviews or market research. We deliver a wide range of syndicated reports that are ready to download today, so you can act on the information right away. And if you don't see what you need in our syndicated reports database, we would be happy to provide you with a customized proposal for proprietary research.

  • >1,000 top tier global thought leaders participate on our proprietary panels
  • >30 indications covered
  • >40 specialties covered

Browse our site to see how MedPredict can provide the thought leader insight you need to make breakthrough strategic decisions.

Reports Coming Soon...

Pancreatic Cancer

Alzheimer's post-ICAD update

Diabetes/Obesity

Acute Coronary Syndrome post-ESC

 

Events...

Come see MedPredict CEO Elizabeth Mathews co-present "Utilizing Thought Leader Research in Competitive Intelligence -- A New Tool for Customizing Your Analysis" at the

 

Psoriasis This report, the 18th in our Psoriasis series, includes the insights from six internationally recognized psoriasis experts (US - 3, Europe - 3 [Switzerland - 1, Germany - 1, and France - 1]). For this report the panelists offered their insight into the following classes of therapeutics for psoriasis and/or psoriatic arthritis (PsA): Antimetabolites, CD-2, CD-4, CD8, CD-11, IL-6, IL-12, IL-17, IL-20, IL-22, IL-23, JAK, p38, protein kinase C, S1P, TNF, and TLR-9. learn more >>

Rheumatology This Thought Leader Panel is based on six interviews conducted with American and European rheumatology thought leaders in July 2010. Topics discussed in this Panel include: New sub-q dose forms; How are diagnostics/biomarkers being developed in concert with antirheumatics?; B-cell approaches; CCR; CD4; CTLA4; JAK; IL-6; IL-17; Interferon; Nerve Growth Factor Antibody; Syk; TNF; and Antiresorptives. learn more >>

 
bottom.gif